<p>Kodiak Sciences Inc. (NASDAQ:KOD - 獲取免費報告) 的股價在週二下跌了 4.2%。該股票最低交易價為 24.60 美元，最後交易價為 25.05 美元。在午間交易中，約有 101,949 股易手，較平均每日交易量 576,602 股下降了 82%。該股票此前收盤價為 26.14 美元。</p>
<p>獲取 <strong>Kodiak Sciences</strong> 的提醒：</p>
<h2>華爾街分析師觀點</h2>
<p>多家研究機構對 KOD 發佈了報告。HC Wainwright 將 Kodiak Sciences 的目標股價從 24.00 美元上調至 26.00 美元，並在 11 月 17 日的報告中給予該公司 “買入” 評級。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Kodiak Sciences 的 “賣出（e+）” 評級。巴克萊將 Kodiak Sciences 的評級從 “減持” 上調至 “持平”，並在 9 月 25 日的研究報告中將該股票的目標股價從 7.00 美元上調至 17.00 美元。傑富瑞金融集團在 9 月 22 日的研究報告中開始覆蓋 Kodiak Sciences，設定了 “買入” 評級和 15.00 美元的目標價。最後，Chardan Capital 在 11 月 17 日的研究報告中重申了 “中性” 評級，並對 Kodiak Sciences 的股票設定了 14.00 美元的目標價。四位股票研究分析師給予該股票 “買入” 評級，兩位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，Kodiak Sciences 的平均評級為 “持有”，共識目標價為 22.67 美元。</p>
<p><strong>查看我們最新的 KOD 股票報告</strong></p>
<h2>Kodiak Sciences 股票表現</h2>
<p>該公司的市值為 13.5 億美元，市盈率為-6.15，貝塔值為 2.68。該公司的 50 日移動平均價格為 18.49 美元，200 日移動平均價格為 11.08 美元。</p>
<p>Kodiak Sciences (NASDAQ:KOD - 獲取免費報告) 最近於 11 月 13 日發佈了其財報。該公司報告每股收益（EPS）為-1.16 美元，低於分析師共識預期的-1.07 美元，差距為 0.09 美元。整體來看，股票分析師預計 Kodiak Sciences Inc.在本年度將發佈-3.45 美元的每股收益。</p>
<h2>對 Kodiak Sciences 的對沖基金觀點</h2>
<p>機構投資者和對沖基金最近增加或減少了對該股票的持倉。US Bancorp DE 在第一季度將其在 Kodiak Sciences 的持股增加了 131.7%。US Bancorp DE 現在擁有 9,282 股該公司的股票，價值 26,000 美元，此前在上個季度又購買了 5,276 股。Headlands Technologies LLC 在第二季度將其在 Kodiak Sciences 的持股增加了 256.4%。Headlands Technologies LLC 現在擁有 8,083 股該公司的股票，價值 30,000 美元，此前在上個季度又收購了 5,815 股。Walleye Capital LLC 在第一季度獲得了 Kodiak Sciences 的一個新頭寸，價值 49,000 美元。Vanguard Personalized Indexing Management LLC 在第二季度將其在 Kodiak Sciences 的持股增加了 21.7%。Vanguard Personalized Indexing Management LLC 現在擁有 15,070 股該公司的股票，價值 56,000 美元，此前在上個季度又購買了 2,691 股。最後，Russell Investments Group Ltd.在第一季度將其在 Kodiak Sciences 的持股增加了 729.9%。Russell Investments Group Ltd.現在擁有 21,039 股該公司的股票，價值 59,000 美元，此前在上個季度又購買了 18,504 股。機構投資者持有該公司 89.06% 的股票。</p>
<h2>關於 Kodiak Sciences</h2>
<p>(獲取免費報告)</p>
<p>Kodiak Sciences Inc.是一家臨牀階段的生物製藥公司，研究、開發和商業化治療視網膜疾病的療法。其主要產品候選藥物為 tarcocimab tedromer (KSI-301)，這是一種抗血管內皮生長因子抗體生物聚合物，目前正在進行治療濕性年齡相關性黃斑變性（AMD）的 IIb/III 期臨牀研究，以及用於治療糖尿病性黃斑水腫、視網膜靜脈阻塞引起的初發黃斑水腫和非增殖性糖尿病視網膜病變的 III 期臨牀研究。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票比 Kodiak Sciences 更好</li>
<li>投資於高市盈率成長股</li>
<li>Carvana 從低點上漲超過 10,000%——現在它進入了標準普爾 500 指數</li>
<li>如何繪製斐波那契價格拐點水平</li>
<li>UiPath 因財報激增：投資者應該追逐這一勢頭嗎？</li>
<li>如何捕捉股息增加的好處</li>
<li>Pure Storage 下跌 27%：真正的機會還是應得的修正？</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Kodiak Sciences 嗎？</h2>
<p>在你考慮 Kodiak Sciences 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已經識別出五隻股票，頂級分析師正在悄悄地向他們的客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Kodiak Sciences 並不在名單上。</p>
<p>雖然 Kodiak Sciences 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

<p>Kodiak Sciences（納斯達克代碼：KOD）股票下跌 4.2%，至 25.05 美元，交易量較平均水平下降 82%。分析師的評級意見不一，普遍目標價為 22.67 美元。該公司報告的季度每股收益為（1.16 美元），未達到預期。機構投資者持有 89.06% 的股份。Kodiak Sciences 專注於視網膜疾病治療，其主要產品正在進行 IIb/III 期臨牀試驗</p>

<p>Kodiak Sciences Inc. (NASDAQ:KOD - Get Free Report)'s share price dropped 4.2% on Tuesday . The stock traded as low as $24.60 and last traded at $25.05. Approximately 101,949 shares changed hands during mid-day trading, a decline of 82% from the average daily volume of 576,602 shares. The stock had previously closed at $26.14.</p>
<div class="lb-trans"><p>Kodiak Sciences Inc. (NASDAQ:KOD - 獲取免費報告) 的股價在週二下跌了 4.2%。該股票最低交易價為 24.60 美元，最後交易價為 25.05 美元。在午間交易中，約有 101,949 股易手，較平均每日交易量 576,602 股下降了 82%。該股票此前收盤價為 26.14 美元。</p>
</div><p>Get <strong>Kodiak Sciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Kodiak Sciences</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>A number of research firms have issued reports on KOD. HC Wainwright boosted their price objective on shares of Kodiak Sciences from $24.00 to $26.00 and gave the company a &#34;buy&#34; rating in a report on Monday, November 17th. Weiss Ratings reissued a &#34;sell (e+)&#34; rating on shares of Kodiak Sciences in a research report on Wednesday, October 8th. Barclays upgraded Kodiak Sciences from an &#34;underweight&#34; rating to an &#34;equal weight&#34; rating and raised their price objective for the stock from $7.00 to $17.00 in a research note on Thursday, September 25th. Jefferies Financial Group began coverage on Kodiak Sciences in a research report on Monday, September 22nd. They set a &#34;buy&#34; rating and a $15.00 target price for the company. Finally, Chardan Capital restated a &#34;neutral&#34; rating and issued a $14.00 price target on shares of Kodiak Sciences in a research report on Monday, November 17th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Kodiak Sciences has an average rating of &#34;Hold&#34; and a consensus price target of $22.67.</p>
<div class="lb-trans"><p>多家研究機構對 KOD 發佈了報告。HC Wainwright 將 Kodiak Sciences 的目標股價從 24.00 美元上調至 26.00 美元，並在 11 月 17 日的報告中給予該公司 “買入” 評級。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Kodiak Sciences 的 “賣出（e+）” 評級。巴克萊將 Kodiak Sciences 的評級從 “減持” 上調至 “持平”，並在 9 月 25 日的研究報告中將該股票的目標股價從 7.00 美元上調至 17.00 美元。傑富瑞金融集團在 9 月 22 日的研究報告中開始覆蓋 Kodiak Sciences，設定了 “買入” 評級和 15.00 美元的目標價。最後，Chardan Capital 在 11 月 17 日的研究報告中重申了 “中性” 評級，並對 Kodiak Sciences 的股票設定了 14.00 美元的目標價。四位股票研究分析師給予該股票 “買入” 評級，兩位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，Kodiak Sciences 的平均評級為 “持有”，共識目標價為 22.67 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on KOD</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 KOD 股票報告</strong></p>
</div><h2>Kodiak Sciences Stock Performance</h2>
<div class="lb-trans"><h2>Kodiak Sciences 股票表現</h2>
</div><p>The company has a market cap of $1.35 billion, a price-to-earnings ratio of -6.15 and a beta of 2.68. The business has a fifty day moving average price of $18.49 and a 200 day moving average price of $11.08.</p>
<div class="lb-trans"><p>該公司的市值為 13.5 億美元，市盈率為-6.15，貝塔值為 2.68。該公司的 50 日移動平均價格為 18.49 美元，200 日移動平均價格為 11.08 美元。</p>
</div><p>Kodiak Sciences (NASDAQ:KOD - Get Free Report) last released its earnings results on Thursday, November 13th. The company reported ($1.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.07) by ($0.09). As a group, equities analysts anticipate that Kodiak Sciences Inc. will post -3.45 EPS for the current year.</p>
<div class="lb-trans"><p>Kodiak Sciences (NASDAQ:KOD - 獲取免費報告) 最近於 11 月 13 日發佈了其財報。該公司報告每股收益（EPS）為-1.16 美元，低於分析師共識預期的-1.07 美元，差距為 0.09 美元。整體來看，股票分析師預計 Kodiak Sciences Inc.在本年度將發佈-3.45 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Kodiak Sciences</h2>
<div class="lb-trans"><h2>對 Kodiak Sciences 的對沖基金觀點</h2>
</div><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. US Bancorp DE raised its holdings in Kodiak Sciences by 131.7% in the 1st quarter. US Bancorp DE now owns 9,282 shares of the company's stock valued at $26,000 after buying an additional 5,276 shares during the last quarter. Headlands Technologies LLC raised its stake in shares of Kodiak Sciences by 256.4% during the second quarter. Headlands Technologies LLC now owns 8,083 shares of the company's stock valued at $30,000 after acquiring an additional 5,815 shares during the last quarter. Walleye Capital LLC acquired a new position in shares of Kodiak Sciences during the first quarter worth $49,000. Vanguard Personalized Indexing Management LLC grew its stake in shares of Kodiak Sciences by 21.7% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,070 shares of the company's stock worth $56,000 after purchasing an additional 2,691 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its stake in shares of Kodiak Sciences by 729.9% in the first quarter. Russell Investments Group Ltd. now owns 21,039 shares of the company's stock worth $59,000 after purchasing an additional 18,504 shares during the last quarter. Institutional investors own 89.06% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近增加或減少了對該股票的持倉。US Bancorp DE 在第一季度將其在 Kodiak Sciences 的持股增加了 131.7%。US Bancorp DE 現在擁有 9,282 股該公司的股票，價值 26,000 美元，此前在上個季度又購買了 5,276 股。Headlands Technologies LLC 在第二季度將其在 Kodiak Sciences 的持股增加了 256.4%。Headlands Technologies LLC 現在擁有 8,083 股該公司的股票，價值 30,000 美元，此前在上個季度又收購了 5,815 股。Walleye Capital LLC 在第一季度獲得了 Kodiak Sciences 的一個新頭寸，價值 49,000 美元。Vanguard Personalized Indexing Management LLC 在第二季度將其在 Kodiak Sciences 的持股增加了 21.7%。Vanguard Personalized Indexing Management LLC 現在擁有 15,070 股該公司的股票，價值 56,000 美元，此前在上個季度又購買了 2,691 股。最後，Russell Investments Group Ltd.在第一季度將其在 Kodiak Sciences 的持股增加了 729.9%。Russell Investments Group Ltd.現在擁有 21,039 股該公司的股票，價值 59,000 美元，此前在上個季度又購買了 18,504 股。機構投資者持有該公司 89.06% 的股票。</p>
</div><h2>About Kodiak Sciences</h2>
<div class="lb-trans"><h2>關於 Kodiak Sciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.</p>
<div class="lb-trans"><p>Kodiak Sciences Inc.是一家臨牀階段的生物製藥公司，研究、開發和商業化治療視網膜疾病的療法。其主要產品候選藥物為 tarcocimab tedromer (KSI-301)，這是一種抗血管內皮生長因子抗體生物聚合物，目前正在進行治療濕性年齡相關性黃斑變性（AMD）的 IIb/III 期臨牀研究，以及用於治療糖尿病性黃斑水腫、視網膜靜脈阻塞引起的初發黃斑水腫和非增殖性糖尿病視網膜病變的 III 期臨牀研究。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Kodiak Sciences</li>
<li>Investing in the High PE Growth Stocks</li>
<li>Carvana Soars Over 10,000% From Lows—Now It’s in the S&amp;P 500</li>
<li>How to Plot Fibonacci Price Inflection Levels</li>
<li>UiPath Surges on Earnings: Should Investors Chase the Momentum?</li>
<li>How to Capture the Benefits of Dividend Increases</li>
<li>Pure Storage's 27% Fall: Real Opportunity or Deserved Correction?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Kodiak Sciences 更好</li>
<li>投資於高市盈率成長股</li>
<li>Carvana 從低點上漲超過 10,000%——現在它進入了標準普爾 500 指數</li>
<li>如何繪製斐波那契價格拐點水平</li>
<li>UiPath 因財報激增：投資者應該追逐這一勢頭嗎？</li>
<li>如何捕捉股息增加的好處</li>
<li>Pure Storage 下跌 27%：真正的機會還是應得的修正？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Kodiak Sciences Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Kodiak Sciences 嗎？</h2>
</div><p>Before you consider Kodiak Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Kodiak Sciences 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已經識別出五隻股票，頂級分析師正在悄悄地向他們的客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Kodiak Sciences 並不在名單上。</p>
</div><p>While Kodiak Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Kodiak Sciences 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Kodiak Sciences（NASDAQ 代碼：KOD）股價下跌 4.2% - 以下是原因